Review of Gardasil
1Professor of Medicine, Director, Center of Excellence in Women’s Health, University of Missouri-Kansas City School of Medicine, Departments of Informatics and Personalized Health, Obstetrics and Gynecology and Community and Family Medicine, USA
- *Corresponding Author:
- Dr. Diane M Harper
Professor of Medicine, Director
Center of Excellence in Women’s Health
University of Missouri-Kansas City School of Medicine
Departments of Informatics and Personalized Health
Obstetrics and Gynecology and Community and Family Medicine Truman Medical Center, Lakewood 7900 Lee’s Summit Road
Kansas City, MO 64139, USA
E-mail: [email protected]
Received Date: October 05, 2010; Accepted Date: November 20, 2010; Published Date: November 23, 2010
Citation: Harper DM, Vierthaler SL, Santee JA (2010) Review of Gardasil. J Vaccin Vaccinat 1:107. doi: 10.4172/2157-7560.1000107
Copyright: © 2010 Harper DM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Human papillomavirus (HPV) is necessary for the development of cervical cancer. Cervical cancer is the second most common cancer in women worldwide but 80% occurs in developing countries, not countries with Pap screening programs. Pap screening programs in industrialized countries have reduced the incidence of cervical cancer to 4-8/100,000 women. HPV vaccines may be a promising strategy for cervical cancer in women without access to screening programs. In industrialized countries, the benefit of HPV vaccines focuses on individual abnormal Pap test reduction not cancer prevention. The focus of this review is to cover the side effects of Gardasil in perspective with the limited population benefit of cervical cancer reduction in countries with organized Pap screening programs. In addition, information about Gardasil benefits, risks and unknowns for individual patient decision making for vaccination is presented. Gardasil offers protection against CIN 2+ lesions caused by HPV 16/18 and against genital warts caused by HPV 6/11 for at least 5 years. Combining Gardasil with repeated cytology screenings may reduce the proportion of abnormal cytology screens by 10% and hence reduce the associated morbidity with the subsequent colposcopies and excisional procedures.